Sanofi anti-allergic drug fexofenadine hydrochloride tablets approved in China

Today (February 19), the drug approval document pending information issued by the National Food and Drug Administration (NMPA) shows that Sanofi's anti-allergic drug fexofenadine hydrochloride has been listed in three applications.

Screenshot source: NMPA official website

There are at least four subtypes of histamine receptors (H1 receptor, H2 receptor, H3 receptor and H4 receptor) in target cells of the human cardiovascular system, skin, smooth muscle and stomach.

Antihistamines targeting histamine H1 receptors can down-regulate the receptors activated by histamine to an inactive state, down-regulate allergic inflammation, reduce the expression of pro-inflammatory cytokines and cell adhesion molecules, and weaken eosinophils Chemotaxis of cells, etc.

Fexofenadine Hydrochloride (Allegra) is a second-generation H1 receptor antagonist developed by Sanofi.

According to information on Sanofi's official website, fexofenadine hydrochloride can inhibit skin flares and flare reactions induced by histamine.

In a number of randomized, double-blind, placebo-controlled clinical trials, 60 mg of fexofenadine hydrochloride and 120 mg of fexofenadine hydrochloride twice a day can effectively reduce the symptoms of seasonal allergic rhinitis (spring Trees and grasses or pollen in autumn) and perennial allergic rhinitis (animal dander, dust mites and mold).

Congratulations to Sanofi's anti-allergic drug fexofenadine hydrochloride tablets for approval in China, giving allergic patients new treatment options!